Japanese Encephalitis - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Japanese Encephalitis - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Japanese Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Japanese Encephalitis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Japanese Encephalitis Overview
3. Therapeutics Development
4. Pipeline Products for Japanese Encephalitis - Overview
5. Pipeline Products for Japanese Encephalitis - Comparative Analysis
6. Japanese Encephalitis - Therapeutics under Development by Companies
7. Japanese Encephalitis - Therapeutics under Investigation by Universities/Institutes
8. Japanese Encephalitis Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Japanese Encephalitis - Products under Development by Companies
13. Japanese Encephalitis - Products under Investigation by Universities/Institutes
14. Japanese Encephalitis - Companies Involved in Therapeutics Development

• Indian Immunologicals Limited
• Kineta, Inc.
• Panacea Biotec Limited
• Vaxine Pty Ltd
• Zydus Cadila Healthcare Limited

For more information visit http://www.researchandmarkets.com/research/vs3rmg/japanese